In­novent, Eli Lil­ly cite a new suc­cess for their PD-1 in lung can­cer, with a like­ly pi­o­neer­ing ap­proval in Chi­na loom­ing

Here come the made-in-Chi­na check­points.

In­novent, one of the most promi­nent op­er­a­tions in the new wave of Chi­nese biotechs that have been go­ing glob­al re­cent­ly, has plucked out da­ta from a sin­gle co­hort of 20 pa­tients to un­der­score the promise of their PD-1 drug sin­til­imab.

In­novent isn’t the on­ly Chi­nese biotech to work on the coun­try’s first wave of lo­cal­ly de­vel­oped check­points. Hen­grui has one, ini­tial­ly al­lied to In­cyte, which moved on to an­oth­er part­ner af­ter some trou­bling rash­es ap­peared in pa­tients. And BeiGene along with Shang­hai Jun­shi are all an­gling for their first Chi­na ap­provals in H1 of next year.

A check of the data­base at Pharm­Cube in Shang­hai re­vealed 68 dif­fer­ent PD-1/L1 drugs in Chi­na’s pipeline, part of the tsuna­mi of check­points that has been form­ing in Asia. End­points’ Am­ber Tong as­sem­bled the full list, which you can see be­low.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER